The DNA polymerase Polθ is synthetic lethal with homologous-recombination deficiency, but a lack of specific targeting compounds has limited its therapeutic potential. Two studies now describe first-in-class inhibitors of Polθ with in vivo efficacy and thus provide alternative therapeutic approaches to PARP inhibitors for cancers deficient in homologous recombination.

中文翻译：

---

未连接的 Polθ 抑制剂

DNA 聚合酶 Polθ 是合成致死的，具有同源重组缺陷，但缺乏特异性靶向化合物限制了其治疗潜力。两项研究现在描述了具有体内功效的一流 Polθ 抑制剂，从而为缺乏同源重组的癌症提供了 PARP 抑制剂的替代治疗方法。